AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase III clinical study titled ‘A Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure.’ The study aims to evaluate the effectiveness and safety of combining baxdrostat with dapagliflozin in treating CKD in patients with high blood pressure.
The study tests two interventions: a combination of baxdrostat and dapagliflozin, and dapagliflozin with a placebo. Baxdrostat is being tested for its potential to enhance the effects of dapagliflozin, a drug already used to treat CKD.
This interventional study follows a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor). The primary purpose is treatment-focused, aiming to determine the efficacy of the drug combination in slowing CKD progression.
The study began on March 29, 2024, with primary completion expected in 2026. The latest update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly impact AstraZeneca’s stock performance by potentially expanding its market share in CKD treatment. Positive results may boost investor confidence, especially in comparison to competitors in the CKD treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.